SPRY

Ars Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 2/10
  • Value↓ 0/10
Ars Pharmaceuticals sales and earnings growth
SPRY Growth
Fair
  • Revenue Y/Y↓ -5.46%
  • EPS Y/Y↓ -2275.00%
  • FCF Y/Y↓ -1418.48%
Ars Pharmaceuticals gross and profit margin trends
SPRY Profitability
Low
  • Gross margin ↑ 75.80%
  • EPS margin↓ -203.30%
  • ROIC 5Y↓ -29.32%
Ars Pharmaceuticals net debt vs free cash flow
SPRY Risk
Good
  • Debt / Equity↓ 1.5
  • Debt / FCF↓ 0.7
  • Interest coverage↓ -64.9

Ars Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.

More Biotechnology stocks ↗